新诊断卵巢癌患者尼拉帕利维持治疗随机3期PRIMA/ENGOT-OV26/GOG-3012试验3.5年随访的无进展生存期与安全性结果
该双盲、安慰剂对照3期试验更新了尼拉帕利一线维持治疗新诊断晚期卵巢癌的长期疗效与安全性。中位无进展生存期随访3.5年时,尼拉帕利在HRd和总体人群中均维持显著PFS获益,未发现新安全性信号。
要点
- HRd人群尼拉帕利组中位PFS 24.5个月 vs 安慰剂组11.2个月,HR 0.52(95%CI 0.40-0.68)。
- 总体人群尼拉帕利组中位PFS 13.8个月 vs 安慰剂组8.2个月,HR 0.66(95%CI 0.56-0.79)。
- 尼拉帕利组最常见≥3级TEAE为血小板减少(39.7%)、贫血(31.6%)和中性粒细胞减少(21.3%)。
核心结论
- 尼拉帕利在新诊断晚期卵巢癌高进展风险患者中维持了具有临床意义的PFS改善,不论HRD状态如何,且未发现新的安全性信号。
研究设计与样本
- 双盲、安慰剂对照、3期PRIMA/ENGOT-OV26/GOG-3012研究(NCT02655016),共随机733例患者(尼拉帕利487例,安慰剂246例),按2:1比例每日一次给药。
- 分层因素为一线化疗最佳缓解(CR/PR)、是否接受新辅助化疗(是/否)及HRD状态(HRd/HRp或未确定)。
主要发现
- 中位INV-PFS随访3.5年,HRd人群尼拉帕利组24.5个月 vs 安慰剂组11.2个月,HR 0.52(95%CI 0.40-0.68)。
- 总体人群尼拉帕利组中位INV-PFS 13.8个月 vs 安慰剂组8.2个月,HR 0.66(95%CI 0.56-0.79)。
- HRp人群尼拉帕利组中位INV-PFS 8.4个月 vs 安慰剂组5.4个月,HR 0.65(95%CI 0.49-0.87)。
- 4年时无进展或死亡比例:HRd人群尼拉帕利组38% vs 安慰剂组17%;总体人群尼拉帕利组24% vs 安慰剂组14%。
- 尼拉帕利组最常见≥3级治疗中出现的不良事件为血小板减少(39.7%)、贫血(31.6%)和中性粒细胞减少(21.3%);骨髓增生异常综合征/急性髓系白血病发生率(1.2%)在尼拉帕利组与安慰剂组相同;总生存期数据尚不成熟。
关键数值与推荐
- HRd人群:尼拉帕利组中位INV-PFS 24.5个月 vs 安慰剂组11.2个月,HR 0.52(95%CI 0.40-0.68)。
- 总体人群:尼拉帕利组中位INV-PFS 13.8个月 vs 安慰剂组8.2个月,HR 0.66(95%CI 0.56-0.79)。
- HRp人群:尼拉帕利组中位INV-PFS 8.4个月 vs 安慰剂组5.4个月,HR 0.65(95%CI 0.49-0.87)。
临床怎么用
- 尼拉帕利维持治疗可用于新诊断晚期卵巢癌高进展风险患者,不论HRD状态,原文结论为维持了具有临床意义的PFS改善。
局限性
- 总生存期数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report updated long-term efficacy and safety from the double-blind, placebo-controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). METHODS: Patients with newly diagnosed advanced ovarian cancer with complete or partial response (CR or PR) to first-line platinum-based chemotherapy received niraparib or placebo once daily (2:1 ratio). Stratification factors were best response to first-line chemotherapy regimen (CR/PR), receipt of neoadjuvant chemotherapy (yes/no), and homologous recombination deficiency (HRD) status (deficient [HRd]/proficient [HRp] or not determined). Updated (ad hoc) progression-free survival (PFS) data (as of November 17, 2021) by investigator assessment (INV) are reported. RESULTS: In 733 randomised patients (niraparib, 487; placebo, 246), median PFS follow-up was 3.5years. Median INV-PFS was 24.5 versus 11.2months (hazard ratio, 0.52; 95% confidence interval [CI], 0.40-0.68) in the HRd population and 13.8 versus 8.2months (hazard ratio, 0.66; 95% CI, 0.56-0.79) in the overall population for niraparib and placebo, respectively. In the HRp population, median INV-PFS was 8.4 versus 5.4months (hazard ratio, 0.65; 95% CI, 0.49-0.87), respectively. Results were concordant with the primary analysis. Niraparib-treated patients were more likely to be free of progression or death at 4years than placebo-treated patients (HRd, 38% versus 17%; overall, 24% versus 14%). The most common grade ≥ 3 treatment-emergent adverse events in niraparib patients were thrombocytopenia (39.7%), anaemia (31.6%), and neutropenia (21.3%). Myelodysplastic syndromes/acute myeloid leukaemia incidence rate (1.2%) was the same for niraparib- and placebo-treated patients. Overall survival remained immature. CONCLUSIONS: Niraparib maintained clinically significant improvements in PFS with 3.5years of follow-up in patients with newly diagnosed advanced ovarian cancer at high risk of progression irrespective of HRD status. No new safety signals were identified.
引用
- González-Martín A, Pothuri B, Vergote I, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023. PMID: 37263896. doi:10.1016/j.ejca.2023.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。